EIF4A1 and diffuse large B-cell lymphoma: In support of our observation, ABC-DLBCL cohorts (n = 260) [which have a worse outcome with standard immune-chemotherapy compared to GCB-DLBCL (Nowakowski and Czuczman 2015)] display higher expression of eIF4A1 compared to GCB-DLBCL (n = 138) (p = 0.032) or UNC-DLBCL (n = 104) (p = 0.191) (Fig. 1B).